Overview

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-07-08

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).

Phase:

PHASE3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

bimekizumab
risankizumab